Related Experiment Video
Updated: Jan 23, 2026

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
Published on: June 15, 2019
Sodium glucose transporter 2 inhibition maintains kidney antibacterial response by decreasing complement C1q
Georg W Sendtner1, Julia Miranda1, Pia Naumann1
1Nephrology Section, Medical Clinic 1, University Hospital Bonn, Rheinische Friedrich-Wilhelms Universität, Bonn, Germany.
Introduction:
Glucose promotes bacterial growth. Sodium-glucose transporter 2 inhibition (SGLT2i), which prevents glucose recovery from the urine, is standard therapy in chronic kidney diseases. However, kidney bacterial infection rates did not increase. Here, we investigated possible underlying mechanisms contributing to this effect.
Methods:
We studied patients and a mouse model of pyelonephritis with and without inhibition of urinary glucose reabsorption using primary murine and human cell culture. Analysis involved a combination of histology, flow cytometry and gene expression analysis.
Results:
Clinical urinary tract infection (UTI) severity and the murine pyelonephritis model reflect a sustained kidney antibacterial response during SGLT2i. A gene expression screen revealed decreased complement C1q expression in pyelonephritic kidneys with SGLT2i along with decreased serum C1q protein. C1q and SGLT2 colocalized in proximal tubules. SGLT2i diminished C1q and modulated surface markers including tyrosine kinase MERTK on the same myeloid cell subset in vivo. In human epithelial cell and peripheral blood mononuclear cell coculture, SGLT2i decreased C1q and MERTK. C1q upregulated MERTK, impaired tumor necrosis factor-α and interleukin-1β secretion and monocyte-mediated neutrophil chemotaxis. Baseline C1q levels were significantly higher in plasma of UK Biobank participants who developed UTI than in propensity score matched control participants.
Conclusions:
Our study delineates regulation of C1q and subsequent monocyte antibacterial functions as a potential mechanism of UTI response regulated by SGLT2i. C1q should also be explored as a possible pathogenic factor in chronic kidney damage amenable to SGLT2i.
Insights
Sodium-glucose transporter 2 inhibition (SGLT2i) surprisingly does not increase urinary tract infection (UTI) risk in kidney disease. SGLT2i regulates complement C1q, enhancing monocyte antibacterial functions and potentially protecting kidneys.
Area of Science:
- Nephrology
- Immunology
- Microbiology
Background:
- Glucose fuels bacterial growth, yet SGLT2 inhibitors (SGLT2i) used in kidney disease don't raise UTI rates.
- Investigating the mechanisms behind this unexpected finding is crucial for patient care.
Purpose of the Study:
- To elucidate the mechanisms by which SGLT2 inhibition impacts kidney bacterial infection response.
- To explore the role of complement C1q in this process.
Main Methods:
- Utilized a mouse model of pyelonephritis and human cell cultures.
- Employed histology, flow cytometry, and gene expression analysis.
- Examined SGLT2 inhibition's effects on urinary glucose, C1q, and myeloid cell markers.
Main Results:
- SGLT2i treatment sustained kidney antibacterial response in pyelonephritis models.
- Decreased complement C1q expression and serum levels were observed with SGLT2i.
- SGLT2i modulated C1q and MERTK on myeloid cells, impacting monocyte antibacterial functions.
Conclusions:
- SGLT2i regulates C1q and monocyte antibacterial functions, explaining the lack of increased UTI risk.
- Complement C1q may be a pathogenic factor in chronic kidney damage and warrants further investigation for SGLT2i therapy.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Kidney Structure
Decreasing Function
Primary Active Transport
Responses to Salt Stress

